Leap Therapeutics (NASDAQ:LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET
Company Participants
Douglas Onsi – President and CEO
Cyndi Sirard – Chief Medical Officer
Jason Baum – Chief Scientific Officer
Conference Call Participants
Matthew Pipps – William Blair
Swayampakula Ramakanth – H.C. Wainwright
Operator
Good morning. Welcome to the Leap Therapeutics Conference Call to discuss Updated Data from Part B of the DeFianCe Study. At this time, all participants are on a listen-only mode. After the speakers’ presentation, there will be a question-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded. I will now pass the conference call over to Doug Onsi, President and Chief Executive Officer of Leap Therapeutics. Doug?
Douglas Onsi
Thank you, and good morning. We’re very excited to have you joining us today for an update on Part B of the DeFianCe Study, our randomized controlled clinical trial of sirexatamab, also known as DKN-01, our first-in-class monoclonal antibody targeting DKK1 in patients with advanced colorectal cancer. I’m Doug Onsi, the CEO with Leap, and with me today are Cynthia Sirard, our Chief Medical Officer; Jay Baum, our Chief Scientific Officer; Chris Mirabelli, our Chairman of the Board, and other members of the Leap Management Team.
In January, we presented initial data demonstrating a double-digit improvement in overall response rate by investigator assessment in the intention-to-treat population, as well as key sub-populations, including patients with left-sided tumors, VEGF-naive, DKK1 biomarker high, previous EGFR therapy, RAS mutational status, and liver and lung metastases. At the time, we indicated that the data on progression free survival was showing early separation in several populations who would need more time to mature. We also indicated that we were confirming the tumor change results using blinded independent central review, the highest standard of radiological review, to ensure that there
Read the full article here